Abstract
Background: Breast cancer patients’ self-understanding of their disease can impact their quality of life (QoL); the relationship between compliance and QoL is poorly understood. Patients and Methods: The Patient’s Anastrozole Compliance to Therapy (PACT) program, a prospective, randomized study, investigated the effect of additional patient information material (IM) packages on compliance with adjuvant aromatase inhibitor (AI) therapy in postmenopausal women with hormone receptor-positive early breast cancer. The QoL subanalysis presented here examined the impact of IM packages on QoL and the association between QoL and compliance. European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and QLQ-BR23 questionnaires were completed at baseline, 12 and 24 months, or study termination to assess health-related QoL and disease-related symptoms. Results: Of the 4,844 patients randomized to standard therapy or standard therapy + IM packages (1:1), 4,253 were available for QoL analysis. No difference in QoL was observed between groups at baseline. IM packages did not have a statistically significant impact on patient QoL at the 12- or 24-month follow-up. Compliant patients experienced improvement in multiple items across the QLQ-C30 and QLQ-BR23 scales at 12 months. However, those results should be interpreted carefully due to limitations in the statistical analyses. Conclusions: Provision of IM packages did not influence patients’ QoL or satisfaction with care during AI therapy. Compliant patients appear to experience improved QoL compared to noncompliant patients, perhaps indicating a more self-empowered perception of their condition.
References
1.
Lemieux
J
, Goodwin
PJ
, Bordeleau
LJ
, Lauzier
S
, Théberge
V
. Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001-2009)
. J Natl Cancer Inst
. 2011
Feb
;103
(3
):178
–231
.
[PubMed]
0027-88742.
Fallowfield
L
, Jenkins
V
. Quality of life issues during adjuvant endocrine therapy
. Cancer Treat Res
. 2009
;151
:353
–65
.
[PubMed]
0927-30423.
Hadji
P
. Menopausal symptoms and adjuvant therapy-associated adverse events
. Endocr Relat Cancer
. 2008
Mar
;15
(1
):73
–90
.
[PubMed]
1351-00884.
Howell
A
, Cuzick
J
, Baum
M
, Buzdar
A
, Dowsett
M
, Forbes
JF
, et al.; ATAC Trialists’ Group
. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer
. Lancet
. 2005
Jan
;365
(9453
):60
–2
.
[PubMed]
0140-67365.
Thürlimann
B
, Keshaviah
A
, Coates
AS
, Mouridsen
H
, Mauriac
L
, Forbes
JF
, et al.; Breast International Group (BIG) 1-98 Collaborative Group
. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
. N Engl J Med
. 2005
Dec
;353
(26
):2747
–57
.
[PubMed]
0028-47936.
Sestak
I
, Cuzick
J
, Sapunar
F
, Eastell
R
, Forbes
JF
, Bianco
AR
, et al.; ATAC Trialists’ Group
. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis
. Lancet Oncol
. 2008
Sep
;9
(9
):866
–72
.
[PubMed]
1470-20457.
Cuzick
J
, Sestak
I
, Baum
M
, Buzdar
A
, Howell
A
, Dowsett
M
, et al.; ATAC/LATTE investigators
. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
. Lancet Oncol
. 2010
Dec
;11
(12
):1135
–41
.
[PubMed]
1470-20458.
Fallowfield
L
, Cella
D
, Cuzick
J
, Francis
S
, Locker
G
, Howell
A
. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial
. J Clin Oncol
. 2004
Nov
;22
(21
):4261
–71
.
[PubMed]
0732-183X9.
Wagner
LI
, Zhao
F
, Goss
PE
, Chapman
JW
, Shepherd
LE
, Whelan
TJ
, et al. Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03)
. Breast Cancer Res Treat
. 2018
Jun
;169
(3
):537
–48
.
[PubMed]
0167-680610.
Fellowes
D
, Fallowfield
LJ
, Saunders
CM
, Houghton
J
. Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for ‘well-tolerated’ treatments?
Breast Cancer Res Treat
. 2001
Mar
;66
(1
):73
–81
.
[PubMed]
0167-680611.
Grunfeld
EA
, Hunter
MS
, Sikka
P
, Mittal
S
. Adherence beliefs among breast cancer patients taking tamoxifen
. Patient Educ Couns
. 2005
Oct
;59
(1
):97
–102
.
[PubMed]
0738-399112.
Hadji
P
. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy
. Crit Rev Oncol Hematol
. 2010
Feb
;73
(2
):156
–66
.
[PubMed]
1040-842813.
Lash
TL
, Fox
MP
, Westrup
JL
, Fink
AK
, Silliman
RA
. Adherence to tamoxifen over the five-year course
. Breast Cancer Res Treat
. 2006
Sep
;99
(2
):215
–20
.
[PubMed]
0167-680614.
Laroche
F
, Perrot
S
, Medkour
T
, Cottu
PH
, Pierga
JY
, Lotz
JP
, et al. Quality of life and impact of pain in women treated with aromatase inhibitors for breast cancer. A multicenter cohort study
. PLoS One
. 2017
Nov
;12
(11
):e0187165
.
[PubMed]
1932-620315.
Kidwell
KM
, Harte
SE
, Hayes
DF
, Storniolo
AM
, Carpenter
J
, Flockhart
DA
, et al. Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy
. Cancer
. 2014
Aug
;120
(16
):2403
–11
.
[PubMed]
0008-543X16.
Hershman
DL
, Shao
T
, Kushi
LH
, Buono
D
, Tsai
WY
, Fehrenbacher
L
, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer
. Breast Cancer Res Treat
. 2011
Apr
;126
(2
):529
–37
.
[PubMed]
0167-680617.
Ruddy
K
, Mayer
E
, Partridge
A
. Patient adherence and persistence with oral anticancer treatment
. CA Cancer J Clin
. 2009
Jan-Feb
;59
(1
):56
–66
.
[PubMed]
0007-923518.
Ma
AM
, Barone
J
, Wallis
AE
, Wu
NJ
, Garcia
LB
, Estabrook
A
, et al. Noncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patients
. Am J Surg
. 2008
Oct
;196
(4
):500
–4
.
[PubMed]
0002-961019.
Partridge
AH
, LaFountain
A
, Mayer
E
, Taylor
BS
, Winer
E
, Asnis-Alibozek
A
. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer
. J Clin Oncol
. 2008
Feb
;26
(4
):556
–62
.
[PubMed]
0732-183X20.
Sedjo
RL
, Devine
S
. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer
. Breast Cancer Res Treat
. 2011
Jan
;125
(1
):191
–200
.
[PubMed]
0167-680621.
Ziller
V
, Kalder
M
, Albert
US
, Holzhauer
W
, Ziller
M
, Wagner
U
, et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer
. Ann Oncol
. 2009
Mar
;20
(3
):431
–6
.
[PubMed]
0923-753422.
Gellad
WF
, Grenard
JL
, Marcum
ZA
. A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity
. Am J Geriatr Pharmacother
. 2011
Feb
;9
(1
):11
–23
.
[PubMed]
1543-594623.
Meggetto
O
, Maunsell
E
, Chlebowski
R
, Goss
P
, Tu
D
, Richardson
H
. Factors Associated With Early Discontinuation of Study Treatment in the Mammary Prevention.3 Breast Cancer Chemoprevention Trial
. J Clin Oncol
. 2017
Feb
;35
(6
):629
–35
.
[PubMed]
0732-183X24.
Harbeck
N
, Blettner
M
, Hadji
P
, Jackisch
C
, Lück
HJ
, Windemuth-Kieselbach
C
, et al. Patient’s Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer
. Breast Care (Basel)
. 2013
May
;8
(2
):110
–20
.
[PubMed]
1661-379125.
Hadji
P
, Blettner
M
, Harbeck
N
, Jackisch
C
, Lück
HJ
, Windemuth-Kieselbach
C
, et al. The Patient’s Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer
. Ann Oncol
. 2013
Jun
;24
(6
):1505
–12
.
[PubMed]
0923-753426.
Aaronson
NK
, Ahmedzai
S
, Bergman
B
, Bullinger
M
, Cull
A
, Duez
NJ
, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology
. J Natl Cancer Inst
. 1993
Mar
;85
(5
):365
–76
.
[PubMed]
0027-887427.
Sprangers
MA
, Groenvold
M
, Arraras
JI
, Franklin
J
, te Velde
A
, Muller
M
, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study
. J Clin Oncol
. 1996
Oct
;14
(10
):2756
–68
.
[PubMed]
0732-183X28.
Cella
D
, Fallowfield
L
, Barker
P
, Cuzick
J
, Locker
G
, Howell
A
; ATAC Trialistsa9 Group
. Quality of life of postmenopausal women in the ATAC (“Arimidex”, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for early breast cancer
. Breast Cancer Res Treat
. 2006
Dec
;100
(3
):273
–84
.
[PubMed]
0167-680629.
Forbes
JF
, Cuzick
J
, Buzdar
A
, Howell
A
, Tobias
JS
, Baum
M
; Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group
. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
. Lancet Oncol
. 2008
Jan
;9
(1
):45
–53
.
[PubMed]
1470-204530.
Cuzick
J
, Sestak
I
, Cella
D
, Fallowfield
L
; ATAC Trialists’ Group
. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial
. Lancet Oncol
. 2008
Dec
;9
(12
):1143
–8
.
[PubMed]
1470-2045© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
